Conditioning regimens are an important issue determining the outcome of hematopoietic stem cell transplantation (HSCT). Less toxicity, early engraftment and no relapse are the aims of efficient conditioning. Our objective was to investigate the long-term effects of BU-CY and their administration order on the toxicity and chimerism in a mouse model of HSCT. Female BALB/c mice were treated with either BU (15 mg/kg/day Â 4)-CY (100 mg/ kg/day Â 2) or CY-BU. Treated mice were transplanted with Sca-1 þ cells from male BALB/c mice. Until 90 days after HSCT, the animals were monitored for body weight and analyzed for cellular phenotype of the thymus, spleen and BM, total chimerism, the spleen chimerism of DCs and T regulatory (Treg) cells, and hepatotoxicity. BU-CY and CY-BU treatments exerted comparable myeloablative and immunosuppressive effects. The long-term engraftment of donor cells in the BM and thymus regeneration showed the same features in both groups. However, the two regimens differed; in general, hepatotoxicity and chimerism of DC and Treg cells. In the long term, BU-CY, but not CY-BU caused a marked decrease in body weight and a significant increase in the activities of the liver enzymes, particularly aspartate amino transferase (AST). We conclude that the alteration of the administration order of BU-CY to CY-BU not only gives the same level of engraftment but also reduces the toxicity of the conditioning regimen that might be valuable specially in young patients who are undergoing HSCT.
Introduction
Hematopoietic stem cell transplantation (HSCT) has been applied successfully for reconstitution of hematolymphopoiesis and provides curative therapy for a number of malignant and nonmalignant diseases. 1 Owing to the rational use of chemotherapy, HSCT protocols have also been developed for other diseases, for example, metabolic and autoimmune disorders. 2, 3 Effective and ideal conditioning regimens should fulfill several criteria including eliminating malignant cells, creating 'enough space' for donor cells in recipient marrow, suppressing the host immune system to prevent graft rejection, eradicate immune memory cells 4 and finally imposing minimal or no toxic effects on the host tissues.
Currently, BU in combination with CY (BU-CY) is used as a conditioning regimen, which, to a large extent, can fulfill the above-mentioned criteria. 5, 6 Despite the controversy concerning survival, the antileukemic and immunosuppressive efficacy of the BU-CY regimen is considered to be equivalent to or even better than TBI in combination with CY (CY-TBI). 7 Moreover, BU offers the advantage of easier administration and better tolerance than TBI in children with hematopoietic malignancies. 8, 9 However, the efficacy of both preparative regimens in the treatment of leukemias is similar, although there seems to be a small advantage for CY-TBI in autologous transplantation for ALLs in terms of leukemia-free survival and relapse incidence. [8] [9] [10] BU is an alkylating agent that affects mainly hematopoietic stem cells and causes marrow ablation. The main toxic action of the drug is the excessive BM depression, which has an effect equal to TBI. 11 BU affects the formation of BM cells in a dose-dependent fashion, that is, at low doses it suppresses the formation of granulocytes and platelets, whereas at high doses it represses the development of erythrocytes. 12 Despite of being an effective myeloablative agent, BU does not possess enough immunosuppressive properties. Therefore, it is most commonly used in combination with an immunosuppressive agent such as CY. CY is an alkylating prodrug, which was introduced into the clinical practice in 1958 and is still one of the most employed anticancer and immunosuppressive drug in the case of HSCT. 13 In spite of improved techniques and new drug invention in recent years, HSCT is still a procedure that is associated with high rate of morbidity and mortality. GVHD, 14 hypothyroidism, 15 cataract, 16 veno-occlusive disorder, 17 interstitial pneumonia, 18 hemorrhagic cystitis 19 and decrement of the quality of life 20 are the most common post-HSCT complications. It is believed that the conditioning regimen plays a crucial role in the development of these complications. 21 Thus, it is of importance to search for alternative or modified conditioning protocols that may improve stem cell engraftment and are devoid of post-HSCT problems. To address this issue, in our previous study on a mouse model for HSCT, we investigated whether altering the administration order of BU-CY to CY-BU could minimize the cytokine storm and toxicity without impairing the efficacy (myeloablation and immunosuppression) of the conditioning regimen. 22 We found that alteration from BU-CY to CY-BU in the conditioning regimen did not impair the efficacy of the regimen. Myeloablative as well as immunosuppressive effects of CY-BU were comparable to BU-CY. 22 However, despite exhibiting similarities in myeloablative and immunosuppressive properties, the two conditioning regimens showed differences in the levels of inflammatory cytokines and liver toxicity expressed as an increase in liver enzymes. 22 These results suggested that altering the administration order of BU-CY might improve the HSCT outcome. 22 In the present investigation, utilizing the syngeneic HSCT mouse model, we performed further studies to test this hypothesis. We investigated the long-term effects of CY-BU and BU-CY as conditioning regimens prior to HSCT on the general toxicity expected as weight retardation, immunosuppression, thymus regeneration, total chimerism, the emergence of donor DCs and CD4 þ CD25 þ T regulatory (Treg) cells, and liver function.
Design and methods

Chemicals
L-a-Phosphatidylcholine and 1,2-dioleolyl-sn-glycero-3-phosphate were obtained from Polar Lipids (Alabaster, AL, USA). Cholesterol (cholest-5-en-3b-ol), BU, CY, phorbol 12-myristate 13-acetate, ionomycin and brefeldin A were purchased from Sigma (St Louis, MO, USA). RPMI1640 medium, PBS, Iscove's modified Dulbecco's medium and FBS were obtained from Invitrogen (Stockholm, Sweden). Stain Buffer (FBS) was supplied by BD Biosciences Pharmingen (San Jose, CA, USA).
Preparation of liposomal BU and CY
Liposomal BU was prepared as described previously. 23 Briefly, L-a-phosphatidylcholine, 1,2-dioleolyl-sn-glycero-3-phosphate and cholesterol were dissolved in chloroform. BU was dissolved in dichloromethane and added to the lipid mixture. The mixture was dried by evaporation until a thin film was formed. Glucose (50 mg/ml) was added and the mixture was filtered under nitrogen pressure using a LiposoFast 50 (Avestin, Ottawa, ON, Canada). Two layers of polycarbonate filters (pore size 100 nm) were used. Liposomal BU was stored at 4 1C until use. Liposomal BU concentration was measured using gas chromatography with electron capture detection, as described previously. 22 CY was dissolved in sterile water, diluted to a final concentration of 8 mg/ml, and stored at 4 1C prior to use.
Animals
Female and male BALB/c (H-2 d ) mice (7-8 weeks old) were purchased from B&K Universal (Sollentuna, Sweden). The mice were housed in acclimatized room with a 12-h dark/ 12-h light cycle with access to standard laboratory chow and water ad libitum. They were allowed to acclimatize to their surrounding for 1 week before starting the treatment. All experiments described herein were approved by the Regional Ethics Committee for Animal Research in accordance with the Animal Protection Law, the Animal Protection Regulation and the Regulation of the Swedish National Board for Laboratory Animals.
Treatment prior stem cell transplantation
Female BALB/c mice were divided into three groups. Group 1 (BU-CY group) received liposomal BU (15 mg/ kg/day) administered as two daily doses for 4 consecutive days (total 60 mg/kg body weight, the dose was chosen according to our previous study 22 ), followed by CY (100 mg/kg/day) for the next 2 days. Group 2 (CY-BU group) received CY during the first 2 days, followed by liposomal BU for the next 4 days at doses mentioned above. Group 3 (control group) was left untreated. All treated animals received their treatments by the intraperitoneal route. Treatment with conditioning regimens was designed to be similar to the clinical setting, that is, it started 7 days before (day -7) stem cell infusion (day 0). There was 24-hour time interval between both drugs, and day -1 was considered as the rest day. The treated and control animals were euthanized on days À5, À3 and 0 prior to HSCT and at days þ 1, þ 3, þ 6, þ 10, þ 20, þ 30, þ 40, þ 60 and þ 90 after HSCT in each group. At each time point three to six mice were used from the control and treated groups, respectively.
BMT
On day 0, male BALB/c mice were killed by cervical dislocation and both femurs removed aseptically. BM was flushed using PBS and single cell suspension was prepared by gently passing through a 14G needle. Mouse stem cells (Sca-1 þ ) were isolated using positive selection with magnetic beads according to the manufacturer's instructions (StemCell Technologies Inc., Vancouver, BC, Canada). Cells were suspended in sterile PBS. Cell number and viability were determined using Trypan blue exclusion assay. Six hundred thousand viable cells, in a total volume of 150 ml, were infused into the lateral tail vein of each female BALB/c mice.
Preparation of single cell suspension of BM, spleen and thymus At appropriate time points, during the conditioning regimens and after HSCT, femurs, spleen and thymus were aseptically removed and collected into a sterile tube containing RPMI 1640 medium. Single cell suspensions were prepared as follows: BM was flushed from the femurs and spleen and thymus were disintegrated using two forceps. BM, spleen and thymus cells were then passed through a cell strainer (70 mM) and rinsed with the same medium. The cell suspension was centrifuged at 250 g for 7 min at 10 1C and the supernatant discarded. Erythrocytes were lysed in BM and spleen (but not thymus) cell suspensions with 3 ml ammonium chloride solution on ice for 3 min. The cells were then washed twice in PBS Dulbecco's without calcium and magnesium under the same centrifuging condition as mentioned above. Finally, cells were resuspended in FBS and cell counts were performed using Tu¨rk solution. Analysis and detection of chimerism using FISH At appropriate intervals after HSCT (days 20, 40, 60 and 90), BM cell suspension was applied onto slides using cytocentrifugation (25 000-50 000 cells/slide). FISH analysis was performed to detect the Y chromosome as described previously. 22 To achieve better conditions for hybridization, digestion of the cell nuclei was performed in a solution of 0.01 M HCl and pepsin (Sigma Chemical Co., St Louis, MO, USA) at þ 37 1C. The probe, a total paint Cy3-labeled mouse chromosome Y DNA (Cambio, Cambridge, UK), was applied to the specimen target area and were simultaneously denatured in a HYBrite chamber (Abbott-Vysis Inc., Downers Grove, IL, USA) at 73 1C for 3 min at 37 1C for 16 h.
Post hybridization washes were done at high stringency to eliminate unspecific hybridization. The slides were then air-dried and counterstained with VectaShield DAPI (4 0 6-diamidine-2-phenylidole-dihydrochloride)/antifade (Vector Laboratories, Burlingame, CA, USA) for easier detection of the cell nuclei.
Slide examination and signal spot counting of chromosome Y was done using a Nikon Eclipse E800 fluorescence microscope equipped with appropriate filter set. In each preparation 500-1000 cells were counted. Results were documented using an Olympus BH-2 microscope also equipped with the appropriate filter sets connected to CytoVision image system (Applied Imaging International Ltd, Newcastle-upon-Tyne, UK).
Fluorescence immunophenotyping and interphase FISH for detection of chimeric CD4 þ CD25 þ and CD11c þ cells A combination of immunofluorescense and the FISH techniques, FICTION, has been used to detect tumor cells within a specific cell population. 24, 25 A modification of this technique was used to detect the donor (chromosome Y þ ) CD4 þ CD25 þ , CD4 þ FoxP3 þ (Treg cells) and CD11c þ (DCs) cell populations in the recipients. Briefly, at appropriate intervals after HSCT (days 20, 40, 60 and 90), spleen and BM cells were applied onto slides by cytocentrifugation (25 000-50 000 cells/slide). Cell slides were air-dried for 12 h and thereafter, fixed with equal parts of methanol and acetone for 90 seconds. Slides were then incubated for 1 h with either FITC-conjugated hamster anti-mouse CD11c or FITC-conjugated rat anti-mouse CD4 in combination with PE-conjugated rat anti-mouse CD25 MoAbs to detect facilitating and Treg cells, respectively (all antibodies were obtained from BD Biosciences Pharmingen). After washing, to detect intracellular forkhead FoxP3 epitope, cell were fixed and incubated in Perm wash solution. PE-conjugated FoxP3 Ab (Santa Cruz Biotechnology, CA, Santa Cruz, USA) at 1:20 dilution was added to the samples and incubated for 1 h in RT. After washing, the slides were mounted in VectaShield antifade solution (Vector Laboratories). After evaluation of the staining and counting of positive cells per 100 cells the cover slips were demounted and the FISH probe, a total paint Cy3-labeled mouse chromosome Y DNA probe (Cambio), was applied without any further pretreatment. The probe and the preparations were simultaneously denatured in a HYBrite (Abbott-Vysis Inc.) at 70 1C for 5 min and hybridized at 37 1C for 2 h. This rather low denaturation temperature maintained the antibody staining better. After stringency washing, the slides were again mounted in the antifade solution before evaluation.
Evaluation of CD11c þ and CD4 þ CD25 þ cells and Y chromosome Evaluation and cell identification was done using an Olympus fluorescence microscope BH60 with adequate filter set equipped with a CCD camera and connected to a Cyto-Vision image system (Applied Imaging Corp., San Jose, CA, USA) in which the results also were documented. All preparations were completely examined using an oil immersion objective with magnification 100 Â 1.3. On all slides stained for CD11c, 25 positive cells were investigated for FISH signal for chromosome Y. The same procedure was performed for the slides stained for CD4/CD25 and CD4FoxP3.
Evaluation of liver function After HSCT, animals were bled at different intervals (days 10, 20, 40, 60 and 90) by retro-orbital puncture under anesthesia and the blood samples were allowed to clot at 4 1C and then centrifuged. The serums were stored at À70 1C until analysis. Liver enzymes aspartate amino transferase (AST) and alanine amino transferase were measured with a Konelab 30i chemistry analyzer (ILS Laboratorie Scandinavia Ab, Sollentuna, Sweden).
Statistical analysis
The data in each table or figure are expressed as means±s.e. Differences between the control and treated groups were analyzed for statistical significance using Mann-Whitney (U-test). All statistical analyses were performed utilizing WinSTAT software (R Fitch Software; Medina AB, Va¨nerborg, Sweden).
Results
General toxicity
General toxicity in mice is defined as change in body weight and other signs such as ruffled fur, lethargy, poor grooming and decrease in activity.
Mice receiving either BU-CY or CY-BU exhibited a significant decrease in the body weight, which started 2 days prior to HSCT and thereafter remained at similar level up to 7 days after HSCT (Figure 1 ). From this time point up to 40 days after HSCT, a recovery of the body weight was observed in both treated groups (Figure 1) . However, while a persistent recovery of body weight was observed in HSCT animals receiving CY-BU until the termination of the experiment (Figure 1 ), mice treated with BU-CY showed a second significant decrease in body weight, which started 40 days after HSCT and lasted until the end of experiment (Figure 1 ).
Myeloablative effect
The myelosuppressive effect of BU-CY and CY-BU in mice before and after HSCT was monitored as the cellularity of the BM in femurs. As shown in Figure 2a , although administration of both preparations induced an effective myelosuppression, apparently BU-CY treatment seems to be more effective in providing space for the donor hematopoietic stem cells than the treatment with CY-BU. That is, on the day of HSCT, the cellularity of the BM in BU-CY-treated animals decreased by 94% (1.2±0.3 Â 10 6 cells/femur), whereas in mice receiving CY-BU, this reduction was about 61% (8.7 ± 1.4 Â 10 6 cells/femur) as compared with untreated controls (19.9 ± 6.6 Â 10 6 cells/ femur). However, long-term monitoring of the BM cellularity did not show a significant difference between these two regimens regarding BM reconstitution (Figure 2a) . Despite that CY-BU regimen induces less myeloablation but in long-term follow-up, chimerism and engraftment level are the same.
Long-term effects on the spleen weight and cellularity Immunosuppressive effects of BU-CY and CY-BU were examined as the weight and cellularity of the spleen before and after HSCT (until 90 days). As demonstrated in Figures 2b and c, both treatments affected spleen in a similar fashion. The wet weight of spleen was decreased on day 0 in BU-CY by 62.2% and CY-BU by 53%, respectively. A significant decrease in the total number of splenocytes was observed on day 0 in BU-CY by 82% and in CY-BU by 80.5%, respectively. The total spleen reconstitution after HSCT was observed on day 3 after CY-BU treatment and on day 6 after BU-CY treatment.
Both treatments produced similar patterns of total splenocyte reconstitution at day 90 (Figure 2c ).
Thymus cellularity and cell phenotype
As shown in Figure 3 , both BU-CY and CY-BU regimens in both short-and long-term follow-up have almost the same effect on thymus regeneration. However, regeneration of thymus tissue (Figure 3a) and repopulation of CD4 þ CD8À cells (Figure 3b ) occur at an earlier time in CY-BU compared with BU-CY group. Cellularity of thymus at day 20 was 117.7 ± 27.92, 196 ± 35.08 and 110.3±8 in BU-CY, CY-BU and the control group, respectively (Figure 3a) . Despite the vast increment of thymus cellularity in CY-BU compared with BU-CY and the control group, the differences were not statistically significant (P40.05). Thymus cellularity converges in both groups to control levels at day 40 and remains unchanged until the end of the study.
The same trend was seen in CD4 þ CD8À population (Figure 3b) . By day 20 after HSCT, CD4 þ CD8À population rose to more than 138% in CY-BU compared with BU-CY-treated mice (P40.05) (Figure 3b ). This might be favorable for earlier immune system reconstitution in children and young adults. Moreover, there was no significant difference in CD4ÀCD8 þ (Figure 3c ) and CD4 þ CD8 þ (Figure 3d ) population between groups throughout the experiment. All values are mean ± s.e. for at least three animals per time point in each group. Differences were analyzed by statistically employing U-test, and treated animals were compared with the control group (*Po0.05, **Po0.01, ***Po0.001).
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BM chimerism
We have previously shown that until 30 days (short term) after HSCT, the BMs of mice treated either with BU-CY or CY-BU exhibited similar levels of chimerism. 22 Thus, to examine the long-term effect of altering administration of BU-CY to CY-BU on chimerism, we monitored the levels of chimerism in the BM until day 90. As illustrated in Figure 4a , the levels of chimerism in the BM were comparable in both groups. The percentage of donor cells increased with time and peaked on day 60 (BU-CY: 77 ± 4% and CY-BU: 78 ± 6%) and thereafter, remained almost at similar levels (BU-CY: 72±4% and CY-BU: 82±6%) until day þ 90 post transplantation. Donor cells detected using FISH are presented in Figure 5a .
Reconstitution of DCs and Treg cells of donor origin
Donor DCs were determined as CD11c þ and chromosome Y þ (Figure 5b ), while donor Treg cells were detected as CD4 þ CD25 þ and chromosome Y þ (Figures 5c and d) . Moreover, to distinguish the true Treg cells from activated CD4 cells due to expression of CD25 in both populations, CD4 cells were stained by intracellular forkhead FoxP3 protein ( Figure 5e ). As shown in Figures 4b and c , the percentage of donor CD11c þ and CD4 þ CD25 þ cells in the spleen of recipient in CY-BU-treated animals was lower than that in mice treated with BU-CY until day 40 after HSCT. However, on days 60 and 90, mice administered with CY-BU exhibited either comparable or even slightly higher numbers of CD11c þ and CD4 þ CD25 þ cells of donor origin in spleen compared with BU-CY-treated animals. As shown in Figure 4d , FoxP3-positive cell chimerism followed the same dynamic and chimerism as CD4 þ CD25 þ cells. This data confirm that donor Treg cell repopulation in CY-BU-treated mice occurs later but is higher compared with that observed after BU-CY treatment.
Long-term effects on the liver function after HSCT
We examined the long-term effects of BU-CY versus CY-BU on the liver function after HSCT by measuring the serum transaminases (AST and alanine amino transferase). Mice treated with BU-CY exhibited higher levels of AST, which reached the highest level on day 90. At this time point, serum AST levels in BU-CY-treated animals were significantly higher (Po0.05) compared with that observed in the mice treated with CY-BU.
The serum levels of alanine amino transferase on day 90 after HSCT in BU-CY-treated mice showed a tendency (P ¼ 0.08) to be higher compared with that seen in CY-BU group. No alterations in alanine amino transferase levels in mice treated with CY-BU were observed compared with the control animals. 
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Discussion
BU is an alkylating agent that mainly acts on slowly proliferating cells. 26, 27 It has little but not enough immunosuppressive property, thus CY was added in both the experimental 5 and clinical settings. 28 Currently, BU-CY combination is a substitute for radiation-based conditioning. Despite the mechanisms of action of BU and TBI being different, the outcome of BU-CY and CY-TBI conditioning regimens are comparable. 21, 29 The ideal pretransplant conditioning aims for earlier engraftment and mixed chimerism, to keep the GVL effect with lower risk of GVHD. Despite increasing numbers of BU-CY-based conditioning in human HSCT, still there is no reliable mouse model of HSCT based on this conditioning.
One of the critical issues of a conditioning regimen is that it should offer an appropriate condition for the engraftment of donor hematopoietic stem cells. 4 Tutschka et al.
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studied syngeneic and allogeneic BMT in the BU-CYtreated rat. The authors were able to demonstrate that 35 mg/kg BU followed by 150 mg/kg CY resulted in adequate immunosuppression for successful and sustained engraftment in the syngeneic setting.
We have previously shown that in the short term after HSCT, mice treated with either BU-CY or CY-BU exhibited similar rates of engraftment. 22 In line with this finding, in the present long-term study, we observed that BU-CY-and CY-BU-treated and stem cell transplanted mice had comparable rates of chimerism in the BM up to 90 days after HSCT. Thus, CY-BU may provide a suitable condition for the donor cell engraftment similar to that by BU-CY.
Our results are comparable with those of Down et al.
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regarding the engraftment through 3-month post transplantation. The myeloablative capacity of our conditioning regimens (both BU-CY and CY-BU) is almost equal to the irradiation therapy used by Down. Moreover, in the syngeneic setting, donor stem and progenitor cells (Sca-1 þ cells) have a similar capacity to induce engraftment at the same level as nucleated BM cells. In addition, both of these nonmyeloablative regimens (BU-CY and CY-BU) are not strong enough to induce engraftment across the allogeneic setting (data not shown), which emphasizes the role of immunological HVG reaction apart from host competitor progenitor cells.
One of the principal issues in BMT, especially in the allogeneic setting, is the induction of engraftment without GVHD. Unfortunately, efforts to reduce GVHD by removing donor T cells from the graft have resulted in poor engraftment and increased relapse rate. 30 Several investigations have shown the importance of donor T regulatory cells and their pivotal role in engraftment and preventing GVHD. 31, 32 In the present investigation, we found that the administration of CY-BU facilitates donor Treg cell engraftment and chimerism equal or better than Effect of BU-CY versus CY-BU on the outcome of HSCT B Sadeghi et al BU-CY both in short and long term. This may lead to better and durable engraftment and, more importantly, less GVHD in the allogeneic setting. On the other hand, Matte et al. 33 have shown that the promotion and intensity of GVHD are mainly due to the donor DCs. We have shown that almost at all studied time points, BU-CY regimen facilitates donor DCs chimerism and their proliferation more than CY-BU group. In our previous report, we have shown that the inflammatory cytokine storm at day 0, which is a critical time for activation of incoming donor cells, is greater after BU-CY compared with that observed after CY-BU regimen. 22 Moreover, inflammatory cytokines are the basis for GVHD initiation and promotion. We speculate that CY-BU regimen seems to be more suitable to avoid GVHD and promote durable engraftment.
The main hallmark of organ toxicity after conditioning and BMT is liver damage. Several studies have shown that liver toxicity was associated with BU levels in patients conditioned with BU and CY. 34 On the other hand, other investigations have shown that toxic metabolites of CY may cause liver toxicity. 35, 36 Therefore, regimen-related toxicity has remained a problem in patients conditioned with BU-CY. 37 The serum levels of the liver enzymes in animals treated with BU-CY were higher compared with that observed in animals treated with CY-BU. In the current long-term (90 days) study, these results are in agreement with our previous report in short-term toxicity of BU-CY and CY-BU regimens.
Together; these results imply that the administration of CY prior to BU might reduce the liver toxicity caused by BU-CY regimen. This finding is also consistent with the recent pharmacokinetic interaction study reported by McCune et al. 38 They have shown that patients treated with BU-CY had a decreased AUC CY and increased AUC HCY (hydroxycyclophosphamide) compared with those found in patients treated with CY-TBI. The authors suggested that these may lead to more liver toxicity in BU-CY versus CY-TBI regimen. CY metabolites mainly HCY (hydroxycyclophosphamide) and CEPM (carboxyethylphosphoramide mustard) are toxic for liver sinusoids cells. 35 Both CY-TBI and BU-CY regimens impair growth in transplanted children and young adults. 34, 37, 39 In the case of BU-CY, it was suggested that BU alone, but not CY can cause growth retardation as was observed in animals conditioned with only BU followed by BMT. 40, 41 In the present study, we have found that growth impairment in long-term follow-up (weight at 90 days) occurred in mice treated with BU-CY, but was not observed in mice treated with CY-BU.
Conditioning prior to HSCT is associated with significant T-cell immunodeficiency. 42 In this respect, the thymus is the primary site of T lymphopoiesis during fetal and early post natal life, its role in reconstitution of the adult immune system after BMT or HSCT remains controversial. 43, 44 In our results, we have observed that both BU-CY and CY-BU groups showed almost the same rate of new T cell (CD4 þ CD8À and CD4ÀCD8 þ ) production in short- Effect of BU-CY versus CY-BU on the outcome of HSCT B Sadeghi et al and long-term follow-up. However, the reconstitution was faster in short term after CY-BU compared with BU-CY. The present results show the importance of conditioning regimen on the thymic regeneration after HSCT. This has to be considered especially in children and young adults.
Our results suggest that altering the administration order from BU-CY to CY-BU reduces general and organspecific toxicity of the regimen, which might benefit patients at high risk, for example, children and young adults. This suggestion is supported by the finding that a pretreatment dose of CY can protect the animals from death and reduce the toxic effects induced by high dose of BU. 40, 41 Moreover, the results are in agreement with our previous report showing the importance of time interval between BU and CY in HSCT patients. 45 In summary, we conclude that the long-term effects of BU-CY and CY-BU as pretransplant conditioning exert similar myeloablative and immunosuppressive effects in the recipient. The BM and spleen recovery as well as the rates of total chimerism in the BM and chimerism of Treg cells in the spleen after HSCT are similar in the recipients treated with BU-CY and CY-BU. However, CY-BU showed to be superior to BU-CY with regard to the drug-related toxicity, that is, the rate of growth retardation and the levels of liver enzymes, which were higher in BU-CYtreated mice compared with that observed in animals treated with CY-BU. Thus, it is conceivable that altering the administration order of conditioning regimen from BU-CY to CY-BU might have a positive impact on the outcome of HSCT especially in children and young adults.
